Download PDF
Semin Thromb Hemost 2019; 45(05): 478-489
DOI: 10.1055/s-0039-1687905
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Primary Prevention of Cardiovascular Events with Aspirin: Toward More Harm than Benefit—A Systematic Review and Meta-Analysis

Mikael Christiansen
1   Department of Clinical Biochemistry, Regional Hospital in Horsens, Horsens, Denmark
,
Erik Lerkevang Grove
2   Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
3   Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark
,
Anne-Mette Hvas
3   Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark
4   Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark
› Author Affiliations
Further Information

Publication History

Publication Date:
16 May 2019 (online)

    Permissions and Reprints

Abstract

Primary prevention of cardiovascular events with aspirin remains controversial, as the risk of bleeding might outweigh the benefits. Recently, new evidence has emerged from the ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events), ASCEND (A Study of Cardiovascular Events in Diabetes), and ASPREE (Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly) trials. The aim of this study was to perform a systematic review and meta-analysis of aspirin's efficacy and safety in the primary prevention of cardiovascular events in healthy individuals and in individuals with cardiovascular risk factors, and separately in those with diabetes. The Medline database was searched, without time restrictions, for relevant human trials published in English up to December 10, 2018, and additional trials were identified from reference lists. Data on efficacy (cardiovascular death and nonfatal myocardial infarction) and safety (major bleeding) were extracted for analysis. In total, 20 randomized trials were identified. Separate meta-analyses were performed on 10 trials including 144,930 individuals, who were healthy or had cardiovascular risk factors, and on 4 trials including 20,326 individuals with diabetes. In healthy individuals and individuals with cardiovascular risk factors, aspirin reduced the risk of nonfatal myocardial infarction by 21% (p < 0.001), but had no effect on cardiovascular death (p = 0.52), and increased the risk of major bleeding by 48% (p < 0.001). In individuals with diabetes, aspirin had no effect on nonfatal myocardial infarction (p = 0.93) or cardiovascular death (p = 0.92) and increased the risk of bleeding by 49% (p = 0.13). This meta-analysis suggests that aspirin should not be used on a routine basis in the primary prevention of cardiovascular events, especially in individuals with diabetes.

Keywords

aspirin - primary prevention - cardiovascular events - safety - diabetes - myocardial infarction

Author Contributions

All authors contributed to the conception and design of the study. All authors provided acquisition of data. M. C. performed data analysis and drafted and finalized the manuscript. All authors interpreted data. All authors read and approved the final manuscript. All authors have accepted responsibility for the entire content of this submitted manuscript and have approved submission.


 

  • References

  • 1 Baigent C, Blackwell L, Collins R. , et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373 (9678): 1849-1860
    CrossrefPubMedGoogle Scholar
  • 2 Lippi G, Danese E, Favaloro EJ. Harms and benefits of using aspirin for primary prevention of cardiovascular disease: a narrative overview. Semin Thromb Hemost 2018 (e-pub ahead of print). doi:10.1055/s-0038-1675380
    PubMedGoogle Scholar
  • 3 Piepoli MF, Hoes AW, Agewall S. , et al; ESC Scientific Document Group. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37 (29) 2315-2381
    CrossrefPubMedGoogle Scholar
  • 4 Bibbins-Domingo K. ; U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2016; 164 (12) 836-845
    CrossrefPubMedGoogle Scholar
  • 5 Sarwar N, Gao P, Seshasai SR. , et al; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375 (9733): 2215-2222
    CrossrefPubMedGoogle Scholar
  • 6 Fox CS, Golden SH, Anderson C. , et al; American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes Research; American Diabetes Association. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2015; 38 (09) 1777-1803
    CrossrefPubMedGoogle Scholar
  • 7 Gaziano JM, Brotons C, Coppolecchia R. , et al; ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018; 392 (10152); 1036-1046
    CrossrefPubMedGoogle Scholar
  • 8 Bowman L, Mafham M, Wallendszus K. , et al; ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018; 379 (16) 1529-1539
    CrossrefPubMedGoogle Scholar
  • 9 McNeil JJ, Wolfe R, Woods RL. , et al; ASPREE Investigator Group. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 2018; 379 (16) 1509-1518
    CrossrefPubMedGoogle Scholar
  • 10 PRISMA. Transparent reporting of systematic reviews and meta-analyses. Available at: http://prisma-statement.org . Accessed July 7, 2018
    PubMed
  • 11 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414): 557-560
    CrossrefPubMedGoogle Scholar
  • 12 Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. ; PPP Collaborative Group. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26 (12) 3264-3272
    CrossrefPubMedGoogle Scholar
  • 13 de Gaetano G. ; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357 (9250): 89-95
    CrossrefPubMedGoogle Scholar
  • 14 Peto R, Gray R, Collins R. , et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296 (6618): 313-316
    CrossrefPubMedGoogle Scholar
  • 15 Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321 (03) 129-135
    CrossrefPubMedGoogle Scholar
  • 16 Ridker PM, Cook NR, Lee IM. , et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352 (13) 1293-1304
    CrossrefPubMedGoogle Scholar
  • 17 Ikeda Y, Shimada K, Teramoto T. , et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014; 312 (23) 2510-2520
    CrossrefPubMedGoogle Scholar
  • 18 Fowkes FG, Price JF, Stewart MC. , et al; Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303 (09) 841-848
    CrossrefPubMedGoogle Scholar
  • 19 Hansson L, Zanchetti A, Carruthers SG. , et al; HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351 (9118): 1755-1762
    CrossrefPubMedGoogle Scholar
  • 20 Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998; 351 (9098): 233-241
    CrossrefPubMedGoogle Scholar
  • 21 Ogawa H, Nakayama M, Morimoto T. , et al; Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300 (18) 2134-2141
    CrossrefPubMedGoogle Scholar
  • 22 Belch J, MacCuish A, Campbell I. , et al; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: a1840
    CrossrefPubMedGoogle Scholar
  • 23 Oz F, Gul S, Kaya MG. , et al. Does aspirin use prevent acute coronary syndrome in patients with pneumonia: multicenter prospective randomized trial. Coron Artery Dis 2013; 24 (03) 231-237
    CrossrefPubMedGoogle Scholar
  • 24 Catalano M, Born G, Peto R. ; Critical Leg Ischaemia Prevention Study (CLIPS) Group. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 2007; 261 (03) 276-284
    CrossrefPubMedGoogle Scholar
  • 25 Erkan D, Harrison MJ, Levy R. , et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007; 56 (07) 2382-2391
    CrossrefPubMedGoogle Scholar
  • 26 Sato H, Ishikawa K, Kitabatake A. , et al; Japan Atrial Fibrillation Stroke Trial Group. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 2006; 37 (02) 447-451
    CrossrefPubMedGoogle Scholar
  • 27 Landolfi R, Marchioli R. European collaboration on low-dose aspirin in polycythemia vera (ECLAP): a randomized trial. Semin Thromb Hemost 1997; 23 (05) 473-478
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Juul-Möller S, Edvardsson N, Jahnmatz B, Rosén A, Sørensen S, Omblus R. ; The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992; 340 (8833): 1421-1425
    CrossrefPubMedGoogle Scholar
  • 29 Baigent C, Blackwell L, Collins R. , et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373 (9678): 1849-1860
    CrossrefPubMedGoogle Scholar
  • 30 Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J 2011; 162 (01) 115-24.e2
    CrossrefPubMedGoogle Scholar
  • 31 Raju N, Sobieraj-Teague M, Hirsh J, O'Donnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011; 124 (07) 621-629
    CrossrefPubMedGoogle Scholar
  • 32 Seshasai SR, Wijesuriya S, Sivakumaran R. , et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172 (03) 209-216
    CrossrefPubMedGoogle Scholar
  • 33 De Berardis G, Sacco M, Strippoli GF. , et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009; 339: b4531
    CrossrefPubMedGoogle Scholar
  • 34 Butalia S, Leung AA, Ghali WA, Rabi DM. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol 2011; 10: 25
    CrossrefPubMedGoogle Scholar
  • 35 Kunutsor SK, Seidu S, Khunti K. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Diabet Med 2017; 34 (03) 316-327
    CrossrefPubMedGoogle Scholar
  • 36 ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992; 268 (10) 1292-1300
    CrossrefPubMedGoogle Scholar
  • 37 Mortensen SB, Larsen SB, Grove EL, Kristensen SD, Hvas AM. Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thromb Res 2010; 126 (04) e318-e322
    CrossrefPubMedGoogle Scholar
  • 38 Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011; 9 (01) 185-191
    CrossrefPubMedGoogle Scholar
  • 39 Neergaard-Petersen S, Hvas AM, Kristensen SD. , et al. The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease. Thromb Haemost 2014; 112 (06) 1142-1150
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Neergaard-Petersen S, Hvas AM, Kristensen SD, Grove EL. Platelets and antiplatelet therapy in patients with coronary artery disease and diabetes. Semin Thromb Hemost 2016; 42 (03) 234-241
    Article in Thieme ConnectPubMedGoogle Scholar